Ultrasound in medicine & biology · 2026
P-50 Sonodynamic Therapy Synergizes With Chemotherapy to Induce Mitochondrial Apoptosis Via ROS Burst in Hepatocellular and Esophageal Carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Peng, Zhang Jing, An Jiaqi, Xu Yulu, Jin Yu, Qiu Mingling, Zhang Chenghong, Wang Bing, Hao Liangyu, Liu Yuhang, Yin Liangwei
Аннотация
OBJECTIVES: P-50 is a novel, water-soluble nanomolar porphyrin polymer that has not yet been explored as a sonosensitizer. This study investigates the effects of P-50-mediated sonodynamic therapy (SDT), in combination with oxaliplatin and cisplatin, on hepatocellular carcinoma (HepG2) and esophageal cancer (Eca-109) cells.
METHODS: The ultrasonic frequency used was 1.0 MHz, with a power of 1.5 W/cm² and a treatment duration of 30 seconds. The cellular uptake of P-50, the cytotoxic effects and apoptosis in SDT alone, chemotherapy drugs, and their combined application on tumor cells were explored.
RESULTS: Results showed efficient uptake of P-50 by both HepG2 and Eca-109 cells. Incubation with 5 μM P-50 for 6 hours exhibited no significant cytotoxicity. Notably, P-50-mediated SDT, when combined with chemotherapy drugs, induced clear signs of late-stage apoptosis and the strongest ROS fluorescence staining in both HepG2 and Eca-109 cells compared to monotherapy. Additionally, an elevated mitochondrial membrane potential was observed in Eca-109 cells, along with the strongest calcium ion fluorescence in HepG2 cells.
CONCLUSIONS: These findings suggest that P-50, possessing minimal inherent cytotoxicity, can serve as an effective sonosensitizer for SDT, promoting apoptosis in HepG2 and Eca-109 cells. Furthermore, combined treatment offers a more potent treatment strategy than monotherapy, enhances apoptosis and antitumor effects likely through ROS upregulation, mitochondrial and calcium disorders triggered by SDT.
METHODS: The ultrasonic frequency used was 1.0 MHz, with a power of 1.5 W/cm² and a treatment duration of 30 seconds. The cellular uptake of P-50, the cytotoxic effects and apoptosis in SDT alone, chemotherapy drugs, and their combined application on tumor cells were explored.
RESULTS: Results showed efficient uptake of P-50 by both HepG2 and Eca-109 cells. Incubation with 5 μM P-50 for 6 hours exhibited no significant cytotoxicity. Notably, P-50-mediated SDT, when combined with chemotherapy drugs, induced clear signs of late-stage apoptosis and the strongest ROS fluorescence staining in both HepG2 and Eca-109 cells compared to monotherapy. Additionally, an elevated mitochondrial membrane potential was observed in Eca-109 cells, along with the strongest calcium ion fluorescence in HepG2 cells.
CONCLUSIONS: These findings suggest that P-50, possessing minimal inherent cytotoxicity, can serve as an effective sonosensitizer for SDT, promoting apoptosis in HepG2 and Eca-109 cells. Furthermore, combined treatment offers a more potent treatment strategy than monotherapy, enhances apoptosis and antitumor effects likely through ROS upregulation, mitochondrial and calcium disorders triggered by SDT.